Despite substantial progress in prevention of perinatal<unk> <unk>  Streptococal (GBS) disease since the 1990s, GBS remains the leading cause of early-onset neonatal sepsis in the United States.  Universal screening at 35--37 weeks' gestation for maternal GBS colonization and use of intrapartum antibiotic prophylaxis has resulted in substantial reductions in the<unk> urden of early-onset GBS disease among newborns. Although early-onset GBS disease has<unk> ecome relatively uncommon in recent years, the rates of maternal GBS colonization (and therefore the risk for early-onset GBS disease in the absence of intrapartum antibiotic prophylaxis) remain unchanged since the 1970s. Continued efforts are needed to sustain and improve on the progress achieved in the prevention of GBS disease. There also is a need to monitor for potential adverse consequences of intrapartum antibiotic prophylaxis (e.g., emergence of<unk> acterial antimicrobial resistance or increased incidence or severity of non-GBS neonatal pathogens). In the absence of a licensed GBS vaccine, universal screening and intrapartum antibiotic prophylaxis continue to<unk> e the cornerstones of early-onset GBS disease prevention.
Group B streptococcal infection
Group A streptococcal infection
Streptococcus pneumoniae infection
Periodic fever syndrome
Pneumococcal infections
Diphtheria
Syphilis
Yersinia pestis infection